Scholars Central

Conference abstractPublished 25 Jul 2023

Assessing the possibilities and risks associated with aurora kinase a targeting drug in breast cancer

Authors: Debomita Sengupta

Chittaranjan National Cancer Institute (CNCI), India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Given the overexpression of Aurora Kinase A (AURKA) in 94% of breast cancer cases, AURKA-inhibitors have been tested without any betterment in response compared to conventional chemotherapeutic regimen proving that AURKA expression is dispensable during dissemination of breast cancer stem cells (BCSCs). In our study, we have observed AURKA upregulation by Oct4/Sox2 indicating that BCSCs may be targeted through AURKA in the cells undergoing active cell-cycle. However, the quiescent BCSCs without AURKA expression were found to circulate in patient blood irrespective of chemotherapeutic regimen demonstrating lack of the proliferative phase as an escaping route against chemotherapeutic regimen or AURKA-targeted therapies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectOncology & Cancer
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Debomita Sengupta”